Kodiak’s Ascent: A Most Peculiar Speculation

by

It has come to my attention – a matter of some consternation, I assure you – that a certain Baker Bros. Advisors LP has seen fit to acquire a substantial parcel of shares in Kodiak Sciences. Two million, six hundred and eight thousand, six hundred and ninety-six, to be precise. A sum that, when tallied, amounts to fifty-three million, four hundred and twenty thousand dollars. One might ask, what manner of fever dream possesses these gentlemen? Or, perhaps more pertinently, what phantom riches do they perceive in this…biopharmaceutical enterprise?

A Most Unusual Transaction

The filing, dated February the seventeenth of this year of our Lord, reveals that Baker Bros. has increased its holdings in Kodiak Sciences, a company engaged in the rather ambitious pursuit of curing retinal diseases. This increase, calculated using the average closing price for the quarter (a practice as reliable as predicting the weather in St. Petersburg, I might add), adds a further two hundred and seventy-three million dollars to their existing investment. A sum that, one suspects, could be better spent on a decent samovar.

Concerning Portfolios and Peculiar Weights

  • Kodiak Sciences now constitutes a full 3.26% of Baker Bros.’ reportable AUM. A trifling amount, one might think, until one considers the sheer absurdity of the underlying investment.
  • Their top holdings, as revealed by the same tedious filings, include INCY at $3.04 billion, ONC at $2.67 billion, MDGL at $1.25 billion, INSM at $1.15 billion, and ACAD, also at $1.15 billion. A veritable menagerie of speculative ventures, each more dubious than the last.
  • And the price! As of February the twenty-third, Kodiak shares were trading at $25.91. A staggering 480% increase over the past year! One begins to suspect a conspiracy involving pigeons trained to inflate stock prices.

A Snapshot of the Enterprise

Metric Value
Market Capitalization $1.6 billion
Net Income (TTM) ($217.34 million)
Price (as of market close February 23, 2026) $25.91

The Company Itself: A Brief and Perplexing Account

  • Kodiak Sciences, it seems, dedicates itself to the development of therapies for retinal diseases, with a leading candidate, KSI-301, currently undergoing trials for wet age-related macular degeneration and other such afflictions. A noble pursuit, perhaps, but one fraught with peril and, more likely, disappointment.
  • Their business model appears to involve the research, development, and potential commercialization of proprietary drug candidates. A rather vague description, wouldn’t you agree? It reminds me of a charlatan selling elixirs in the marketplace.
  • They are, in essence, a clinical-stage biopharmaceutical company based in the United States. A location known for its…enthusiasm for innovation, and its equally impressive capacity for financial extravagance.

Kodiak Sciences, therefore, is a company specializing in innovative therapies for retinal diseases. Or, as I suspect, a beautifully constructed house of cards waiting for the slightest breeze to bring it tumbling down.

What Does This Mean for the Discerning Investor?

Kodiak’s momentum, they say, is building. Tarcocimab and KSI-501 are both enrolled in the Phase 3 DAYBREAK study, with data expected in the third quarter. GLOW2, for diabetic retinopathy, is on track for this quarter. And KSI-101 is advancing in PEAK and PINNACLE. A flurry of activity, to be sure, but one that obscures the fundamental question: is there any actual substance beneath all the hype? The opportunity, they claim, lies within a $15 billion anti-VEGF marketplace. A marketplace, I might add, already teeming with competitors and plagued by the relentless march of scientific progress.

The financials, unsurprisingly, reflect this ambition. Third quarter R&D spending reached $50.5 million, with a quarterly net loss of $61.5 million. Cash stood at $72 million at September 30, before a rather desperate $184 million raise in December. A precarious situation, to say the least. Within a portfolio already heavy in oncology and metabolic biotech, a 3% weight is…tolerable. But for long-term investors, the thesis hinges on non-inferiority and durability. If Phase 3 data validate the ABC platform, Kodiak could compete head-on in retinal vascular disease. If not…well, a 480% run leaves precious little margin for error. One might as well wager one’s entire fortune on a game of chance.

Read More

2026-02-23 21:22